MLLT3 and precursor B-cell acute lymphoblastic leukemia: Lastly, in order to evaluate the therapeutic potential of I-BET151 in vivo, we took advantage of a humanized bone marrow xenograft model (huBM-sc) of secondary MLL-AF9-driven B-ALL that we have previously published [29].